Cancer stem cells in hematological disorders: Current and possible new therapeutic approaches

Current Pharmaceutical Biotechnology

Volumn 12, Issue 2, 2011, Pages 217-225

  Annaloro, C ^a   Onida, F ^a,b   Saporiti, G ^a,b   Deliliers, G Lambertenghi ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Hematopoietic niche; Leukemia; Leukemic niche; Leukemic stem cell; Targeted therapy

Indexed keywords

ARSENIC TRIOXIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BEVACIZUMAB; BORTEZOMIB; CANTHARIDIN; CD135 ANTIGEN; CEDIRANIB; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; LESTAURTINIB; LONAFARNIB; MEMBRANE ANTIGEN; MIDOSTAURIN; MONOCLONAL ANTIBODY; NIMESULIDE; RETINOIC ACID; SORAFENIB; SUNITINIB; TANDUTINIB; TELOMERASE; THALIDOMIDE; TIPIFARNIB;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; EPIGENETICS; GENE MUTATION; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PROMYELOCYTIC LEUKEMIA;

MUS;

EID: 79551628694     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794295747     Document Type: Article

References (116)

1. Till, J.E.; Mc, C. E. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res., 1961, 14, 213-222.
2. Morrison, S. J.; Weissman, I. L. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity, 1994, 1(8), 661-673.
3. Tsiftsoglou, A. S.; Bonovolias, I. D.; Tsiftsoglou, S. A. Multilevel targeting of hematopoietic stem cell self-renewal, differentiation and apoptosis for leukemia therapy. Pharmacol. Ther., 2009, 122(3), 264-280.
4. Bonnet, D.; Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 1997, 3(7), 730-737.
5. Gribben, J. G. In: Thomas' Hematopoietic Stem Cell Transplantation; 3rd ed.; Blume, K. G. F. S.; Appelbaum, F. R., Eds., Blackwell Publishing 2004; p. 244.
6. Mimeault, M.; Batra, S. K. Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res. Rev., 2009, 8(2), 94-112.
7. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M. A.; Dick, J. E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 1994, 367(6464), 645-648.
8. Krause, D. S.; Van Etten, R. A. Right on target: eradicating leukemic stem cells. Trends Mol. Med., 2007, 13(11), 470-481.
9. Hope, K. J.; Jin, L.; Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in selfrenewal capacity. Nat. Immunol., 2004, 5(7), 738-743.
10. Satoh, C.; Ogata, K. Hypothesis: myeloid-restricted hematopoietic stem cells with self-renewal capacity may be the transformation site in acute myeloid leukemia. Leuk. Res., 2006, 30(4), 491-495.
11. Vickers, M.; Brown, G. C.; Cologne, J. B.; Kyoizumi, S. Modelling haemopoietic stem cell division by analysis of mutant red cells. Br. J. Haematol., 2000, 110(1), 54-62.
12. Hawkins, E. D.; Russell, S. M. Upsides and downsides to polarity and asymmetric cell division in leukemia. Oncogene, 2008, 27(55), 7003-7017.
13. Burkhardt, R.; Frisch, B.; Bartl, R. Bone biopsy in haematological disorders. J. Clin. Pathol., 1982, 35(3), 257-284.
14. Schofield, R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells, 1978, 4(1-2), 7-25.
15. Lane, S. W.; Scadden, D. T.; Gilliland, D. G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood, 2009, 114(6), 1150-1157.
16. Adams, G. B.; Chabner, K. T.; Alley, I. R.; Olson, D. P.; Szczepiorkowski, Z. M.; Poznansky, M. C.; Kos, C. H.; Pollak, M. R.; Brown, E. M.; Scadden, D. T. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature, 2006, 439(7076), 599-603.
17. Kiel, M. J.; Yilmaz, O. H.; Iwashita, T.; Terhorst, C.; Morrison, S. J. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell, 2005, 121(7), 1109-1121.
18. Perry, J. M.; Li, L. Disrupting the stem cell niche: good seeds in bad soil. Cell, 2007, 129(6), 1045-1047.
19. Konopleva, M.; Tabe, Y.; Zeng, Z.; Andreeff, M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist. Updat., 2009, 12(4-5), 103-113.
20. Podar, K.; Chauhan, D.; Anderson, K. C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia, 2009, 23(1), 10-24.
21. Lataillade, J. J.; Pierre-Louis, O.; Hasselbalch, H. C.; Uzan, G.; Jasmin, C.; Martyre, M. C.; Le Bousse-Kerdiles, M. C. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood, 2008, 112(8), 3026-3035.
22. Greiner, J.; Dohner, H.; Schmitt, M. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica, 2006, 91(12), 1653-1661.
23. Jamieson, C. H.; Ailles, L. E.; Dylla, S. J.; Muijtjens, M.; Jones, C.; Zehnder, J. L.; Gotlib, J.; Li, K.; Manz, M. G.; Keating, A.; Sawyers, C. L.; Weissman, I. L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med., 2004, 351(7), 657-667.
24. Lee, J. T.; Herlyn, M. Old disease, new culprit: tumor stem cells in cancer. J. Cell. Physiol., 2007, 213(3), 603-609.
25. Misaghian, N.; Ligresti, G.; Steelman, L. S.; Bertrand, F. E.; Basecke, J.; Libra, M.; Nicoletti, F.; Stivala, F.; Milella, M.; Tafuri, A.; Cervello, M.; Martelli, A. M.; McCubrey, J. A. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia, 2009, 23(1), 25-42.
26. Wang, G. P.; Qi, Z. H.; Chen, F. P. Treatment of acute myeloid leukemia by directly targeting both leukemia stem cells and oncogenic molecule with specific scFv-immunolipoplexes as a deliverer. Med. Hypotheses, 2008, 70(1), 122-127.
27. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001, 293(5531), 876-880.
28. Jiang, X.; Saw, K. M.; Eaves, A.; Eaves, C. Instability of BCRABL gene in primary and cultured chronic myeloid leukemia stem cells. J. Natl. Cancer Inst., 2007, 99(9), 680-693.
29. Jiang, X.; Zhao, Y.; Smith, C.; Gasparetto, M.; Turhan, A.; Eaves, A.; Eaves, C. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia, 2007, 21(5), 926-935.
30. Shah, N. P.; Nicoll, J. M.; Nagar, B.; Gorre, M. E.; Paquette, R. L.; Kuriyan, J.; Sawyers, C. L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2002, 2(2), 117-125.
31. Hu, Y.; Chen, Y.; Douglas, L.; Li, S. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia, 2009, 23(1), 109-116.
32. Wang, L.; O'Leary, H.; Fortney, J.; Gibson, L. F. Ph+/VEcadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells. Blood, 2007, 110(9), 3334-3344.
33. Tabe, Y.; Jin, L.; Tsutsumi-Ishii, Y.; Xu, Y.; McQueen, T.; Priebe, W.; Mills, G. B.; Ohsaka, A.; Nagaoka, I.; Andreeff, M.; Konopleva, M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrowderived stromal cells. Cancer Res., 2007, 67(2), 684-694.
34. Apostolidou, E.; Kantarjian, H. M.; Verstovsek, S. JAK2 inhibitors: A reality? A hope? Clin. Lymphoma Myeloma, 2009, 9(Suppl 3), S340-345.
35. Li, L.; Neaves, W. B. Normal stem cells and cancer stem cells: the niche matters. Cancer Res., 2006, 66(9), 4553-4557.
36. Potter, M. D.; Barbero, S.; Cheresh, D. A. Tyrosine phosphorylation of VE-cadherin prevents binding of p120-and beta-catenin and maintains the cellular mesenchymal state. J. Biol. Chem., 2005, 280(36), 31906-31912.
37. Sanz, M. A. Treatment of acute promyelocytic leukemia. Hematol. Am. Soc. Hematol. Educ. Prog., 2006, 147-155.
38. Zheng, X.; Seshire, A.; Ruster, B.; Bug, G.; Beissert, T.; Puccetti, E.; Hoelzer, D.; Henschler, R.; Ruthardt, M. Arsenic but not alltrans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica, 2007, 92(3), 323-331.
39. Estey, E.; Dohner, H. Acute myeloid leukaemia. Lancet, 2006, 368(9550), 1894-1907.
40. Rowe, J. M. Optimal induction and post-remission therapy for AML in first remission. Hematol. Am. Soc. Hematol. Educ. Prog., 2009, 396-405.
41. Guzman, M. L.; Jordan, C.T. Considerations for targeting malignant stem cells in leukemia. Cancer Control, 2004, 11(2), 97-104.
42. Jordan, C. T. Can we finally target the leukemic stem cells? Best Pract. Res. Clin. Haematol., 2008, 21(4), 615-620.
43. Taussig, D. C.; Miraki-Moud, F.; Anjos-Afonso, F.; Pearce, D. J.; Allen, K.; Ridler, C.; Lillington, D.; Oakervee, H.; Cavenagh, J.; Agrawal, S. G.; Lister, T. A.; Gribben, J. G.; Bonnet, D. Anti- CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood, 2008, 112(3), 568-575.
44. Hauswirth, A. W.; Florian, S.; Printz, D.; Sotlar, K.; Krauth, M. T.; Fritsch, G.; Schernthaner, G. H.; Wacheck, V.; Selzer, E.; Sperr, W. R.; Valent, P. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur. J. Clin. Invest., 2007, 37(1), 73-82.
45. Giles, F.; Estey, E.; O'Brien, S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer, 2003, 98(10), 2095-2104.
46. McKoy, J. M.; Angelotta, C.; Bennett, C. L.; Tallman, M. S.; Wadleigh, M.; Evens, A. M.; Kuzel, T. M.; Trifilio, S. M.; Raisch, D. W.; Kell, J.; DeAngelo, D. J.; Giles, F. J. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk. Res., 2007, 31(5), 599-604.
47. Estey, E. New drugs in acute myeloid leukemia. Semin. Oncol., 2008, 35(4), 439-448.
48. Taussig, D. C.; Pearce, D. J.; Simpson, C.; Rohatiner, A. Z.; Lister, T. A.; Kelly, G.; Luongo, J. L.; Danet-Desnoyers, G. A.; Bonnet, D. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood, 2005, 106(13), 4086-4092.
49. Vercauteren, S.; Zapf, R.; Sutherland, H. Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(-) AML patients express CD33. Cytotherapy, 2007, 9(2), 194-204.
50. Tavor, S.; Petit, I.; Porozov, S.; Avigdor, A.; Dar, A.; Leider-Trejo, L.; Shemtov, N.; Deutsch, V.; Naparstek, E.; Nagler, A.; Lapidot, T. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res., 2004, 64(8), 2817-2824.
51. Ponta, H.; Sherman, L.; Herrlich, P. A. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell. Biol., 2003, 4(1), 33-45.
52. Avigdor, A.; Goichberg, P.; Shivtiel, S.; Dar, A.; Peled, A.; Samira, S.; Kollet, O.; Hershkoviz, R.; Alon, R.; Hardan, I.; Ben-Hur, H.; Naor, D.; Nagler, A.; Lapidot, T. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood, 2004, 103(8), 2981-2989.
53. Smadja-Joffe, F.; Coulombel, L. [Targeting of CD44 to eradicate leukemic stem cells]. Med. Sci., (Paris), 2006, 22(11), 1003-1005.
54. Jin, L.; Hope, K. J.; Zhai, Q.; Smadja-Joffe, F.; Dick, J. E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med., 2006, 12(10), 1167-1174.
55. Jordan, C. T.; Upchurch, D.; Szilvassy, S. J.; Guzman, M. L.; Howard, D. S.; Pettigrew, A. L.; Meyerrose, T.; Rossi, R.; Grimes, B.; Rizzieri, D. A.; Luger, S. M.; Phillips, G. L. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia, 2000, 14(10), 1777-1784.
56. Jin, L.; Lee, E. M.; Ramshaw, H. S.; Busfield, S. J.; Peoppl, A. G.; Wilkinson, L.; Guthridge, M. A.; Thomas, D.; Barry, E. F.; Boyd, A.; Gearing, D. P.; Vairo, G.; Lopez, A. F.; Dick, J. E.; Lock, R. B. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell, 2009, 5(1), 31-42.
57. van Rhenen, A.; Moshaver, B.; Kelder, A.; Feller, N.; Nieuwint, A.W.; Zweegman, S.; Ossenkoppele, G. J.; Schuurhuis, G. J. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia, 2007, 21(8), 1700-1707.
58. Testa, U.; Riccioni, R.; Militi, S.; Coccia, E.; Stellacci, E.; Samoggia, P.; Latagliata, R.; Mariani, G.; Rossini, A.; Battistini, A.; Lo-Coco, F.; Peschle, C. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood, 2002, 100(8), 2980-2988.
59. Du, X.; Ho, M.; Pastan, I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J. Immunother., 2007, 30(6), 607-613.
60. Cohen, K. A.; Liu, T. F.; Cline, J. M.; Wagner, J. D.; Hall, P. D.; Frankel, A. E. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol. Immunother., 2005, 54(8), 799-806.
61. Songyang, Z.; Shoelson, S. E.; Chaudhuri, M.; Gish, G.; Pawson, T.; Haser, W. G.; King, F.; Roberts, T.; Ratnofsky, S.; Lechleider, R. J. SH2 domains recognize specific phosphopeptide sequences. Cell, 1993, 72(5), 767-78
62. Unkeless, J. C.; Jin, J. Inhibitory receptors, ITIM sequences and phosphatases. Curr. Opin. Immunol., 1997, 9(3), 338-343.
63. Bakker, A. B.; van den Oudenrijn, S.; Bakker, A. Q.; Feller, N.; van Meijer, M.; Bia, J. A.; Jongeneelen, M. A.; Visser, T. J.; Bijl, N.; Geuijen, C. A.; Marissen, W. E.; Radosevic, K.; Throsby, M.; Schuurhuis, G. J.; Ossenkoppele, G. J.; de Kruif, J.; Goudsmit, J.; Kruisbeek, A. M. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res., 2004, 64(22), 8443-8450.
64. van Rhenen, A.; van Dongen, G. A.; Kelder, A.; Rombouts, E. J.; Feller, N.; Moshaver, B.; Stigter-van Walsum, M.; Zweegman, S.; Ossenkoppele, G. J.; Jan Schuurhuis, G. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood, 2007, 110(7), 2659-2666.
65. Zhao, X.; Singh, S.; Pardoux, C.; Zhao, J.; Hsi, E. D.; Abo, A.; Korver, W. Targeting C-type lectin-like molecule-1 for antibodymediated immunotherapy in acute myeloid leukemia. Haematologica, 2010, 95(1), 71-78.
66. Mikesch, J. H.; Steffen, B.; Berdel, W. E.; Serve, H.; Muller-Tidow, C. The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Leukemia, 2007, 21(8), 1638-1647.
67. Reya, T.; Duncan, A. W.; Ailles, L.; Domen, J.; Scherer, D. C.; Willert, K.; Hintz, L.; Nusse, R.; Weissman, I. L. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature, 2003, 423(6938), 409-414.
68. Willert, K.; Brown, J. D.; Danenberg, E.; Duncan, A. W.; Weissman, I. L.; Reya, T.; Yates, J. R 3rd.; Nusse, R. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature, 2003, 423(6938), 448-452.
69. Polakis, P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev., 2007, 17(1), 45-51.
70. van Es, J. H.; Barker, N.; Clevers, H. You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr. Opin. Genet. Dev., 2003, 13(1), 28-33.
71. Yang, J.; Chai, L.; Gao, C.; Fowles, T.C.; Alipio, Z.; Dang, H.; Xu, D.; Fink, L. M.; Ward, D.C.; Ma, Y. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood, 2008, 112(3), 805-813.
72. Yang, J.; Chai, L.; Liu, F.; Fink, L. M.; Lin, P.; Silberstein, L. E.; Amin, H. M.; Ward, D. C.; Ma, Y. Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc. Natl. Acad. Sci. USA, 2007, 104(25), 10494-10499.
73. Kuhnlein, R. P.; Schuh, R. Dual function of the region-specific homeotic gene spalt during Drosophila tracheal system development. Development, 1996, 122(7), 2215-2223.
74. Kohlhase, J.; Heinrich, M.; Schubert, L.; Liebers, M.; Kispert, A.; Laccone, F.; Turnpenny, P.; Winter, R. M.; Reardon, W. Okihiro syndrome is caused by SALL4 mutations. Hum. Mol. Genet., 2002, 11(23), 2979-2987.
75. Fasano, C. A.; Phoenix, T. N.; Kokovay, E.; Lowry, N.; Elkabetz, Y.; Dimos, J. T.; Lemischka, I. R.; Studer, L.; Temple, S. Bmi-1 cooperates with Foxg1 to maintain neural stem cell self-renewal in the forebrain. Genes. Dev., 2009, 23(5), 561-574.
76. Hitzler, J. K.; Soares, H. D.; Drolet, D. W.; Inaba, T.; O'Connel, S.; Rosenfeld, M. G.; Morgan, J. I.; Look, A. T. Expression patterns of the hepatic leukemia factor gene in the nervous system of developing and adult mice. Brain Res., 1999, 820(1-2), 1-11.
77. Wang, G. S. Medical uses of mylabris in ancient China and recent studies. J. Ethnopharmacol., 1989, 26(2), 147-162.
78. Dorn, D. C.; Kou, C. A.; Png, K. J.; Moore, M. A. The effect of cantharidins on leukemic stem cells. Int. J. Cancer, 2009, 124(9), 2186-2199.
79. Hisa, T.; Spence, S. E.; Rachel, R. A.; Fujita, M.; Nakamura, T.; Ward, J. M.; Devor-Henneman, D. E.; Saiki, Y.; Kutsuna, H.; Tessarollo, L.; Jenkins, N. A.; Copeland, N.G. Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. EMBO J., 2004, 23(2), 450-459.
80. Alcalay, M.; Tiacci, E.; Bergomas, R.; Bigerna, B.; Venturini, E.; Minardi, S. P.; Meani, N.; Diverio, D.; Bernard, L.; Tizzoni, L.; Volorio, S.; Luzi, L.; Colombo, E.; Lo Coco, F.; Mecucci, C.; Falini, B.; Pelicci, P.G. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood, 2005, 106(3), 899-902.
81. Argiropoulos, B.; Humphries, R. K. Hox genes in hematopoiesis and leukemogenesis. Oncogene, 2007, 26(47), 6766-6776.
82. Dedhar, S.; Williams, B.; Hannigan, G. Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol., 1999, 9(8), 319-323.
83. Hannigan, G. E.; Bayani, J.; Weksberg, R.; Beatty, B.; Pandita, A.; Dedhar, S.; Squire, J. Mapping of the gene encoding the integrinlinked kinase, ILK, to human chromosome 11p15.5-p15.4. Genomics, 1997, 42(1), 177-179.
84. Hannigan, G. E.; Leung-Hagesteijn, C.; Fitz-Gibbon, L.; Coppolino, M. G.; Radeva, G.; Filmus, J.; Bell, J. C.; Dedhar, S. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature, 1996, 379(6560), 91-96.
85. Muranyi, A. L.; Dedhar, S.; Hogge, D. E. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk. Res., 2010, 34(10),1358-1365.
86. Burnett, A. K.; Knapper, S. Targeting treatment in AML. Hematol. Am. Soc. Hematol. Edu. Program, 2007, 429-234.
87. End, D. W. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest. New Drugs, 1999, 17(3), 241-258.
88. Harousseau, J. L.; Lancet, J. E.; Reiffers, J.; Lowenberg, B.; Thomas, X.; Huguet, F.; Fenaux, P.; Zhang, S.; Rackoff, W.; De Porre, P.; Stone, R. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood, 2007, 109(12), 5151-5156.
89. Lancet, J. E.; Gojo, I.; Gotlib, J.; Feldman, E. J.; Greer, J.; Liesveld, J. L.; Bruzek, L. M.; Morris, L.; Park, Y.; Adjei, A. A.; Kaufmann, S. H.; Garrett-Mayer, E.; Greenberg, P. L.; Wright, J. J.; Karp, J. E. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood, 2007, 109(4), 1387-1394.
90. Guzman, M. L.; Neering, S. J.; Upchurch, D.; Grimes, B.; Howard, D. S.; Rizzieri, D. A.; Luger, S.M.; Jordan, C.T. Nuclear factorkappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 2001, 98(8), 2301-7.
91. Pyatt, D. W.; Stillman, W. S.; Yang, Y.; Gross, S.; Zheng, J. H.; Irons, R. D. An essential role for NF-kappaB in human CD34(+) bone marrow cell survival. Blood, 1999, 93(10), 3302-3308.
92. Guzman, M. L.; Swiderski, C. F.; Howard, D. S.; Grimes, B. A.; Rossi, R. M.; Szilvassy, S. J.; Jordan, C. T. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. USA, 2002, 99(25), 16220-16225.
93. Guzman, M. L.; Rossi, R. M.; Karnischky, L.; Li, X.; Peterson, D. R.; Howard, D. S.; Jordan, C. T. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood, 2005, 105(11), 4163-4169.
94. Guzman, M. L.; Rossi, R. M.; Neelakantan, S.; Li, X.; Corbett, C. A.; Hassane, D. C.; Becker, M. W.; Bennett, J. M.; Sullivan, E.; Lachowicz, J. L.; Vaughan, A.; Sweeney, C. J.; Matthews, W.; Carroll, M.; Liesveld, J. L.; Crooks, P. A.; Jordan, C. T. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 2007, 110(13), 4427-4435.
95. Humbert, P. O.; Grzeschik, N. A.; Brumby, A. M.; Galea, R.; Elsum, I.; Richardson, H. E. Control of tumourigenesis by the Scribble/ Dlg/Lgl polarity module. Oncogene, 2008, 27(55), 6888-6907.
96. Januschke, J.; Gonzalez, C. Drosophila asymmetric division, polarity and cancer. Oncogene, 2008, 27(55), 6994-7002.
97. Russell, S. How polarity shapes the destiny of T cells. J. Cell. Sci., 2008, 121(Pt 2), 131-136.
98. Deville, L.; Hillion, J.; Segal-Bendirdjian, E. Telomerase regulation in hematological cancers: a matter of stemness? Biochim. Biophys. Acta, 2009, 1792(4), 229-239.
99. Lansdorp, P. M. Self-renewal of stem cells. Biol. Blood Marrow Transplant., 1997, 3(4), 171-178.
100. Harrison, D. E.; Astle, C. M.; Delaittre, J. A. Loss of proliferative capacity in immunohemopoietic stem cells caused by serial transplantation rather than aging. J. Exp. Med., 1978, 147(5), 1526-1531.
101. Small, D. Targeting FLT3 for the treatment of leukemia. Semin. Hematol., 2008, 45(3 Suppl 2), S17-21.
102. Arseni, N.; Ahmed, F.; Hiddemann, W.; Buske, C.; Feuring-Buske, M. Effects of the protein tyrosine kinase inhibitor, SU5614, on leu kemic and normal stem cells. Haematologica, 2005, 90(11), 1577-1578.
103. Piloto, O.; Levis, M.; Huso, D.; Li, Y.; Li, H.; Wang, M. N.; Bassi, R.; Balderes, P.; Ludwig, D. L.; Witte, L.; Zhu, Z.; Hicklin, D. J.; Small, D. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/ severe combined immunodeficient mice. Cancer Res., 2005, 65(4), 1514-1522.
104. Piloto, O.; Nguyen, B.; Huso, D.; Kim, K. T.; Li, Y.; Witte, L.; Hicklin, D. J.; Brown, P.; Small, D. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/ severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res., 2006, 66(9), 4843-4851.
105. Smith, B. D.; Levis, M.; Beran, M.; Giles, F.; Kantarjian, H.; Berg, K.; Murphy, K. M.; Dauses, T.; Allebach, J.; Small, D. Singleagent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood, 2004, 103(10), 3669-3676.
106. Knapper, S.; Burnett, A. K.; Littlewood, T.; Kell, W. J.; Agrawal, S.; Chopra, R.; Clark, R.; Levis, M. J.; Small, D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 2006, 108(10), 3262-3270.
107. DeAngelo, D. J.; Stone, R. M.; Heaney, M. L.; Nimer, S. D.; Paquette, R. L.; Klisovic, R. B.; Caligiuri, M. A.; Cooper, M. R.; Lecerf, J. M.; Karol, M. D.; Sheng, S.; Holford, N.; Curtin, P. T.; Druker, B. J.; Heinrich, M. C. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood, 2006, 108(12), 3674-3681.
108. Fiedler, W.; Serve, H.; Dohner, H.; Schwittay, M.; Ottmann, O. G.; O'Farrell, A. M.; Bello, C. L.; Allred, R.; Manning, W. C.; Cherrington, J. M.; Louie, S. G.; Hong, W.; Brega, N. M.; Massimini, G.; Scigalla, P.; Berdel, W. E.; Hossfeld, D. K. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 2005, 105(3), 986-993.
109. O'Farrell, A. M.; Foran, J. M.; Fiedler, W.; Serve, H.; Paquette, R. L.; Cooper, M. A.; Yuen, H. A.; Louie, S. G.; Kim, H.; Nicholas, S.; Heinrich, M. C.; Berdel, W. E.; Bello, C.; Jacobs, M.; Scigalla, P.; Manning, W. C.; Kelsey, S.; Cherrington, J. M. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res., 2003, 9(15), 5465-5476.
110. Stone, R. M.; De Angelo, J.; Galinsky, I.; Estey, E.; Klimek, V.; Grandin, W.; Lebwohl, D.; Yap, A.; Cohen, P.; Fox, E.; Neuberg, D.; Clark, J.; Gilliland, D. G.; Griffin J. D. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann. Hematol., 2004, 83(Suppl. 1), S89-90.
111. Karp, J. Future research directions for the treatment of AML. Clin. Adv. Hematol. Oncol., 2008, 6(11), 8-10.
112. Levis, M.; Pham, R.; Smith, B. D.; Small, D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood, 2004, 104(4), 1145-1150.
113. Brown, P.; Levis, M.; McIntyre, E.; Griesemer, M.; Small, D. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia, 2006, 20(8), 1368-1376.
114. Brown, P.; Levis, M.; Shurtleff, S.; Campana, D.; Downing, J.; Small, D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood, 2005, 105(2), 812-820.
115. Yeh, J. R.; Munson, K. M.; Elagib, K. E.; Goldfarb, A. N.; Sweetser, D. A.; Peterson, R. T. Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat. Chem. Biol., 2009, 5(4), 236-243.
116. Miyamoto, T.; Weissman, I. L.; Akashi, K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc. Natl. Acad. Sci. USA, 2000, 97(13), 7521-7526.